Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review

Basit Öğe Kaydı
dc.contributor.authorTemiz, Selami Aykut
dc.contributor.authorAbdelmaksoud, Ayman
dc.contributor.authorWollina, Uwe
dc.contributor.authorKutlu, Omer
dc.contributor.authorDursun, Recep
dc.contributor.authorPatil, Anant
dc.contributor.authorLotti, Torello
dc.date.accessioned2024-02-23T14:24:29Z
dc.date.available2024-02-23T14:24:29Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIntroduction The pandemic caused by the novel coronavirus disease 2019 (COVID-19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower-than-hoped-for rollout, particularly for low-to-middle-income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS-CoV-2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute Respiratory Distress Syndrome. The safety profile of these vaccines needs is closely assessed. Methods This comprehensive review includes searching the PubMed, EMBASE, and Web of Science databases using the keywords coronavirus, COVID-19, vaccine, cutaneous reactions, allergic reactions, and SARS-CoV-2. Manual searching of reference lists of included articles augmented the research. The research was updated in June 2021. Results In this narrative review, we tried to investigate and discuss the cutaneous and allergic reactions related to SARS-CoV-2 vaccines currently available in the literature. As a result, although COVID-19 vaccines can be reported to develop allergic and anaphylactic reactions, especially after m-RNA vaccines, they remain at a low rate, and it is observed that these reactions may develop more frequently, especially in patients with previous allergies and mast cell disorders. Fortunately, these reactions are generally transient, benign, self-limited. Conclusion Although there is still no definitive evidence, as dermatologists, we must be aware of the possibility of cutaneous reactions, newly diagnosed dermatoses, or exacerbation of existing dermatoses that may develop after the COVID-19 vaccinations.en_US
dc.identifier.doi10.1111/jocd.14613
dc.identifier.endpage12en_US
dc.identifier.issn1473-2130
dc.identifier.issn1473-2165
dc.identifier.issue1en_US
dc.identifier.pmid34791757en_US
dc.identifier.scopus2-s2.0-85119129567en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage4en_US
dc.identifier.urihttps://doi.org/10.1111/jocd.14613
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13965
dc.identifier.volume21en_US
dc.identifier.wosWOS:000719636100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Cosmetic Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAllergic Reactionsen_US
dc.subjectBnt162b2en_US
dc.subjectCovid-19en_US
dc.subjectCutaneous Reactionsen_US
dc.subjectSars-Cov-2en_US
dc.subjectVaccinationen_US
dc.titleCutaneous and Allergic reactions due to COVID-19 vaccinations: A reviewen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu